DelveInsight’s “Cerebral Amyloid Angiopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cerebral Amyloid Angiopathy, historical and forecasted epidemiology as well as the Cerebral Amyloid Angiopathy market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Cerebral Amyloid Angiopathy Overview
Cerebral Amyloid Angiopathy also called cerebrovascular amyloidosis, is a cerebrovascular disorder caused by the accumulation of cerebral amyloid-β (Aβ) in the tunica media and adventitia of leptomeningeal and cortical vessels of the brain. The resultant vascular fragility tends to manifest in normotensive elderly patients as lobar intracerebral hemorrhage. It is a common cerebral amyloid deposition disease, affecting ~90% of Alzheimer’s patients and increasing the risk of stroke, brain hemorrhage, or dementia. The exact etiology of CAA is not fully understood. It is characterized by congophilic material (amyloid-beta 40 peptides) being deposited into the leptomeninges and small to medium-sized cerebral blood vessels. This deposition weakens vessel walls, making them prone to bleeding. CAA can occur in certain familial syndromes or can occur sporadically.
Cerebral Amyloid Angiopathy Epidemiology Insights:
According to Kort et al. (2019), based on a neuropathological examination, the prevalence of moderate-to-severe Cerebral Amyloid Angiopathy in Alzheimer’s disease (AD) is 48% and in the general population 23%. The prevalence based on MRI criteria was remarkably lower: 22% in AD and 7% in the general population.
According to Robinson et al. (2011), the most serious manifestation in older people is the rupture of cerebral vessels, leading to primary intracerebral hemorrhage (PICH). PICH accounts for ∼10% of all strokes in the United Kingdom.
According to Steven et al. (2022), the prevalence is strongly age-dependent. The prevalence of CAA ranged from 2.3% for patients between the ages of 65 and 74, 8.0% for those aged 75 to 84, and 12.1% in patients over the age of 85.
According to Holmes et al. (2017), in a community-based autopsy cohort, CAA was shown to be more common in demented versus non-demented individuals with an overall frequency of 84.9% (13); 57.8% had mild to moderate CAA, and 18.9% had moderate to severe Cerebral Amyloid Angiopathy.
Click here to learn more about Cerebral Amyloid Angiopathy Market Landscape
The Report Covers the Cerebral Amyloid Angiopathy Epidemiology Segmented by –
Cerebral Amyloid Angiopathy prevalent cases
Cerebral Amyloid Angiopathy incident cases
Cerebral Amyloid Angiopathy treatment cases
Cerebral Amyloid Angiopathy diagnosed cases
Cerebral Amyloid Angiopathy Market Outlook
The Cerebral Amyloid Angiopathy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cerebral Amyloid Angiopathy market trends by analyzing the impact of current Cerebral Amyloid Angiopathy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Cerebral Amyloid Angiopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cerebral Amyloid Angiopathy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Cerebral Amyloid Angiopathy market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies in the Cerebral Amyloid Angiopathy Market Include:
Sorento Therapeutics
Prothena Therapeutics
Takeda Pharmaceuticals
Spectrum Pharmaceuticals
Millineum Pharmaceuticals
Alnylm Pharmaceuticals
And many more
Cerebral Amyloid Angiopathy Therapies Covered in the Report Include:
Taxifolin
Galantamine
Rivastigmine
Donepezil
Aducanumab
Memantine
And many others
Learn more about the Key Companies and the Emerging Therapies in the Cerebral Amyloid Angiopathy Market
Table of Contents
Key Insights
Report Introduction
Executive Summary of Cerebral Amyloid Angiopathy
Disease Background and Overview
Epidemiology and patient population
Cerebral Amyloid Angiopathy Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Click here to read more about the report’s offerings @ Cerebral Amyloid Angiopathy Market Outlook
Trending Reports by DelveInsight
Adalimumab Biosimilar Market
Arbovirus Infection Market
Artificial Pancreas Device System Market
Dental Equipment Market
Gluten Sensitivity Market
Hypothyroidism Market
Inflammatory Bowel Disease Market
Mayus Kinase Jak Inhibitors Market
Mild Dry Eye Market
Mucopolysaccharidosis Market
Oncolytic Virus Cancer Therapy Market
Pyoderma Gangrenosum Market
Transdermal Drug Delivery Devices Market
Intrathecal Pumps Market
Hedgehog Pathway Inhibitors Market
Yellow Fever Market
Laryngeal Cancer Market
Female Infertility Market
Gender Dysphoria Market
Chronic Brain Damage Market
Spain Healthcare Outlook Market
Malignant Fibrous Histiocytoma Market
Related Reports
Cerebral Amyloid Angiopathy Pipeline Insights
The “Cerebral Amyloid Angiopathy – Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Cerebral Amyloid Angiopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
